| INTRODUC TI ON
Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the world. 1 Despite recent progress in chemotherapeutic options, including mAb therapeutics, the prognosis for metastatic CRC is still very poor. Of the mAb therapies for CRC, mAbs against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) are clinically available. 2, 3 Although EGFR is expressed in several normal tissues, the mAb can preferentially accumulate in CRC tumor tissues as a result of the enhanced permeability and retention effect of tumor tissue. 4, 5 However, because EGFR is expressed at a high level in normal skin tissue, skin toxicity is common, and cessation of mAb treatment is sometimes inevitable even if the therapy is effective in patients. 6, 7 In the case of anti-VEGF mAb, some patients receiving the mAb have life-threatening side-effects including serious bleeding and gastrointestinal perforation. 8 In this context, we need to find a new CRC-specific molecule and develop mAb against the molecule in order to produce an effective antibody therapy in the treatment of metastatic CRC with minimal side-effects.
To find a CRC-specific molecule, comprehensive expression analysis is usually carried out between CRC cells and their normal counterpart, mucoepithelial cells. However, in reality, obtaining pure live normal mucoepithelial cells is more difficult than obtaining CRC cells even if a laser micro-dissection method is used. We have reported that many mucoepithelial cells are exfoliated in stool, some of which
The present state of therapy for colorectal cancer (CRC) is far from satisfactory, highlighting the need for new targets for this disease. We identified a new CRC-specific molecule, TMEM180, a predicted 11-pass transmembrane protein that apparently functions as a cation symporter. We developed an anti-TMEM180 mAb and then succeeded in humanizing the mAb. Immunohistochemistry (IHC) in CRC with the mAb showed a similar positivity rate as compared with anti-epidermal growth factor receptor mAb, and IHC with anti-TMEM180 mAb did not show staining in major organs used in this study. Immune electron microscopy clearly indicated that TMEM180 was present on the tumor exosome. The TMEM180 promoter region contains 10 hypoxiaresponsive element consensus sequences; accordingly, SW480 cells upregulated TMEM180 under low-oxygen conditions. Anti-TMEM180 mAb has in vitro antibodydependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity, and SW480 CRC xenografts were eradicated by the mAb. These data indicate that TMEM180 may be a new CRC marker and that a mAb against this protein could be used as antibody-based therapy against CRC.
K E Y W O R D S
antibody drug, antibody therapy, diagnosis by tumor marker and biomarker, gastrointestinal tract, tumor antigen contain intact mRNA. 9 Based on the results, we previously developed a method for obtaining almost pure normal mucoepithelial cells from lavage solution following colonoscopies of healthy examinees. We then identified several new CRC-specific molecules after comprehensive expression analyses between the pure mucoepithelial cells and the CRC cell lines. 10 TMEM180 was one of them and is a predicted 11-pass transmembrane protein (UniProtKB, http://www.uniprot.org/ uniprot/). In the present study, we developed a mAb against TMEM180
and evaluated the potential of using its mAb for CRC therapy.
| MATERIAL S AND ME THODS

| Collection of human samples
Human exfoliated colonocytes in a saline mucosal wash fluid were obtained from two healthy donors at the time of their colonoscopy examination. Cell purification and processing methods were conducted as previously described.
10
The experimental protocols and procedures were approved by the institutional review board of the National Cancer Center, Japan.
All methods were carried out in accordance with the relevant guidelines and regulations. 
| Cells and cell culture
| DNA microarray
DNA microarray analysis was conducted using 10 μg total RNA from colon cancer cells or exfoliated colonocytes and the Affymetrix GeneChip Human Genome U133 plus 2.0 arrays; the analysis was conducted according to standard Affymetrix protocols. 12 In the microarray analysis, 91 genes encoding membrane proteins, which were highly expressed in CRC cells but not in the colonocytes from healthy donors, were selected from 38 500 genes contained in the chip array.
| Real-time quantitative RT-PCR
RNA extraction and qRT-PCR were conducted as previously described. 13 
| In situ hybridization
In situ hybridization was conducted as previously described. 
| Antibodies
Hybridoma cells producing anti-TMEM180 monoclonal antibodies 
| Immunohistochemistry
Human specimens were purchased from BioChain Institute, Inc (Newark, CA, USA). Immunohistochemistry (IHC) was carried out as previously described. 15 Anti-TMEM180 antibody or anti-EGFR mAb (cetuximab, Merck, Darmstadt, Germany) was labeled with HRP using Peroxidase Labeling Kit-SH (Dojindo). Tissues were then incubated with the HRP-conjugated anti-TMEM180 mAb or anti-EGFR mAb for 1 hour at room temperature. After the tissue was washed with PBS, the reaction was visualized using diaminobenzidine (DAB) (Dako, Santa Clara, CA, USA), and the slides were counterstained with hematoxylin.
For cell staining, cultured cells were fixed with 4% PFA/PBS.
After permeabilization with 0.1% Triton X-100/PBS and blocking with 5% skimmed milk, the cells were stained with R-phycoerythrinlabeled anti-TMEM180 using R-Phycoerythrin Labeling Kit-SH TBS-T, proteins were visualized using ECL prime (GE Healthcare). The images were acquired using a ChemiDoc imager (Bio-Rad).
| Flow cytometry
Flow cytometry was conducted as previously described method. 
| Animal model and antitumor activity
Female BALB/c nude mice (5 weeks old) were purchased from Charles River Laboratories Japan Inc (Kanagawa, Japan).
To 
| Database analysis
Number of hypoxia response element consensus sequences (ACGTG 
| Generation of TMEM180 KO mice
TMEM180 gene KO mice were generated using CRISPR/Cas9-mediated genome editing technology. 27 Briefly, guide RNAs (gRNAs) at exon 2 of mouse TMEM180 genome immediately downstream of the ATG start codon were designed using CRISPRdirect. 28 Two gRNAs [gS01(5′-AGCTGTGGTGTACGGCTCGTTGG-3′), gS03(5′-TGTGTTCCTGCTGTACTACGTGG-3′)] were selected in an in vitro digestion assay system 29 using the target TMEM180 PCR product.
These two gRNAs were inserted into the BbsI restriction site in the px330 plasmid and constructed as a px330-TMEM180 genome editing vector.
Pronuclear stage ova of C57BL/6J (Clea Japan, Tokyo, Japan)
were prepared by in vitro fertilization and injection of 1.67 ng/ μL px330-TMEM180 DNA vector into the pronucleus according to standard protocols. 30 The injected ova were transferred into the oviduct of the pseudopregnant Jcl:MCH (Clea Japan) female on that day.
Two viable mice from gS01 and 14 viable mice from gS03 were obtained independently by cesarean section. Genotyping of mouse tail DNA by PCR [forward (5′-CTAATAGGCAACCGCAGAGC-3′), reverse (5′-CTAAACAGCACAGTCTGCCC-3′)] and purified PCR products were sequenced using the forward primer. Results of the sequence analysis are shown in Table S1 .
| Statistical analysis
Significant differences between the groups were determined using Student's t test for ELISA data, ANOVA to compare tumor size and body weight, and chi-squared test. All analyses were carried out using SPSS software version 20 (IBM, Armonk, NY, USA).
| RE SULTS
| Identification and characterization of TMEM180 as a new CRC marker
We previously developed a method to obtain almost pure normal mucoepithelial cells from the lavage solution following colonoscopies of healthy examinees using immune beads with anti-EpCAM mAb. 10 Moreover, the previous study reported a comprehensive DNA microarray analysis comparing CRC cell lines (SW480, LoVo, DLD-1, HT-29 and HCT116) and normal mucoepithelial cells. 10 We reanalyzed these microarray data and found that TMEM180 
| First production of anti-TMEM180 antibody with a recombinant TMEM180 peptide
To evaluate the potential of TMEM180 as a new target for the diagnosis and/or therapy of CRC, we attempted to produce a mAb.
However, the TMEM180 gene is predicted to encode an 11-pass transmembrane protein with limited extracellular domain expression. First, we immunized rats with a recombinant extracellular domain of the TMEM180 protein and obtained an IgM mAb. During the evaluation process, we unexpectedly noticed that the TMEM180 protein was present in the culture supernatant of SW480 and DLD-1 CRC cells. We collected the supernatant and subjected it to hydroxyapatite and gel filtration chromatography. We found that a high concentration of the TMEM180 protein existed in the void fraction ( Figure S2A ).
As a result of the detection of TMEM180 in the culture supernatant, we hypothesized that TMEM180 coexisted with exosomes or other extracellular microparticles. To test whether TMEM180
exists on tumor-derived exosomes, we conducted immune electron microscopy for the enriched exosomes with CD9 or CD63 mAbs and the TMEM180 mAb. The images clearly indicated that TMEM180 was present on the tumor exosome, similar to CD9 and CD63 ( Figure S2B ). In the sandwich ELISA, both TMEM180-positive and CD9-positive exosomes were detected ( Figure S2C ). We concluded that the tumor exosomes released from DLD-1 cells contain TMEM180.
| Second production of anti-TMEM180 antibody with TMEM180-positive exosomes and validation of a CRC-specific target
We judged that purifying the full-length TMEM180 protein while maintaining the native structure necessary for producing a useful mAb recognizable for the live cell would be the most difficult step. Moreover, we thought that several mAbs with a higher affinity could be obtained by antigens with native structure. Therefore, we immunized rats again with TMEM180-positive tumor exosomes purified from the supernatant of DLD-1 cells. The newly obtained anti-TMEM180 mAb (IgM, clone 669) was able to recognize most CRC cells, but not hematopoietic cells ( Figure S3A,B) .
We then converted the rat IgM to humanized IgG1 in order to evaluate the potential for therapeutic application of the mAb. First, we examined the expression of TMEM180 in CRC and normal major tissues (colon, skin, liver, brain, kidney, lung and heart) by IHC. Cetuximab 
| Diagram and functional role of TMEM180
TMEM180 is classified in the major facilitator superfamily and appears to function as a cation symporter ( Figure 3A) . To address the func- Figure 3B ). We investigated the uptake of glutamine and arginine in the cation symport mechanism because the utilization of both amino acids was strongly increased in tumor cells. 31, 32 We found that SW480-WT cells were capable of growing in a serum-free medium with glutamine and arginine. By contrast, both KD1 and KD2
could not grow in the same medium ( Figure 3C ). These findings suggest TMEM180 has an important role in the uptake or metabolism of glutamine and arginine in tumor growth and proliferation. Preliminary experiments showed that cetuximab exerted statistically significant antitumor effects in both tumor xenografts. In the case of anti-TMEM180 mAb, the antitumor effect was significant in DLD-1 xenografts. Strikingly, all SW480 xenografts were completely eradicated by the anti-TMEM180 mAb. We then confirmed these results using a dosage of 25 or 12.5 mg/kg given twice a week for a total of eight injections for both mAbs in mice bearing DLD-1 or SW480 xenografts, respectively. In mice with the DLD-1 xenografts, both anti-TMEM180 mAb and cetuximab showed a significant antitumor effect compared to the control treatment ( Figure 4A ). In mice with the SW480 xenografts, cetuximab showed a significant antitumor effect at 25 mg/kg but not at 12.5 mg/kg. In contrast, anti-TMEM180 mAb elicited a striking antitumor effect, eradicating the tumor at both 25 and 12.5 mg/kg ( Figure 4A ). There was no significant difference in the treatment-related body weight loss among the five groups ( Figure 4B ).
| Biological characteristics of TMEM180 expression in CRC cells and tissues
Using a public database to analyze the promoter region of the TMEM180 gene, we found that there were 10 hypoxia response element consensus sequences 22, 23 in the gene ( Figure 5A ). Moreover, HIF-1α expression was elevated in both DLD-1 and SW480 cells in hypoxic conditions ( Figure 5B ). We therefore evaluated the change in TMEM180 expression in response to the same treatment. Hypoxia significantly increased TMEM180 mRNA expression in SW480 cells and also tended to increase expression in DLD-1 cells ( Figure 5C ).
Protein expression level of TMEM180 was significantly increased in both DLD-1 and SW480 cells after hypoxia treatment ( Figure 5D ,E).
Therefore, TMEM180 expression in CRC cells is regulated by hypoxia. 
| D ISCUSS I ON
In the present study, we identified a new CRC-specific molecule, TMEM180, by taking advantage of our original method, 9,10 and succeeded in establishing a mAb against TMEM180 followed by humanizing it. The expression profile of TMEM180 differed from the expression profile of EGFR, and TMEM180 mAb staining was almost absent in normal tissues, unlike staining with the EGFR mAb. We also found that TMEM180 was expressed at levels as high as the levels of other existing markers such as EGFR and CD44 in cancers and at extremely low levels compared to the levels of other molecules in normal tissues ( Figure S6 ). We, therefore, think that the tumor specificity of TMEM180 is substantially higher than that of other molecules. In further experiments, we found that the TMEM180 gene had 10 hypoxia response element consensus sequences, which may be HIF-1α binding sites controlled by hypoxia. 22, 23, 33 Recent studies have indicated that not only hypoxia but also chemotherapy induces HIF-1α expression followed by T-cell anergy and increased dissemination of cancer cells. 34 HIF-1α is currently considered a key factor of cancer stem cell function. In cancer tissues, unlike in normal tissues, angiogenesis and hypoxia associated with the necrosis caused by cancer-induced blood coagulation are repeated alternately during clinical progression. [35] [36] [37] However, HIF-1α is upregulated in many types of cancer besides CRC. Therefore, another transcription factor specific in CRC might regulate TMEM180 expression in conjunction with HIF-1α. Further molecular and translational studies are needed to elucidate the detailed biological role of TMEM180 and the antitumor mechanism of its targeting therapy.
Safety of a drug should also be considered for therapeutic use in clinical practice. According to the database, TMEM180 mRNA is hardly expressed in any normal tissues ( Figure S4A) . Also, the expression of TMEM180 is extremely low in all organs compared to the expression of other known CRC markers. In the present study, IHC also showed that there was no TMEM180 expression in all major organs studied.
Finally, we succeeded in obtaining a TMEM180 gene KO mouse that does not show embryonic, neonatal, and postnatal lethality (Table S1 ).
According to these data, we expect that unpredictable adverse effects are unlikely to occur in a clinical trial of anti-TMEM180 mAb.
Our mAb is now being processed according to Good Manufacturer Practice principles for testing in a first-in-human clinical trial. We think that there are several concerns to be clarified before entering a clinical trial. We must investigate further antitumor activity using other CRC cell lines and PDX tumors. We will make progress on the functional analysis of TMEM180 including the involvement in glutamine and arginine metabolism as a cation transporter after obtaining an F2 generation of the KO mice. We hope that a future clinical trial will verify the significance of the mAb for the treatment of CRC. 
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